Macular Degeneration: Donati G

Donati G. · Clinique d'Ophtalmologie de Genève, HUG, Geneva, Switzerland. · Ophthalmologica. · Pubmed #17947822 No free full text.

Abstract: The cornerstone of pharmacotherapeutic treatment for age-related macular degeneration (AMD) is photodynamic therapy with verteporfin. The recently approved pegaptanib sodium, which targets vascular endothelial growth factor (VEGF), reduces vision loss in AMD when given by intravitreal injection every 6 weeks. The early promise of monotherapy with the corticosteroid triamcinolone acetonide has yet to be borne out in larger clinical trials, but outcomes may be improved when it is used in combination with verteporfin therapy. The angiostatic cortisone anecortave acetate was recently reported to have failed to meet the primary efficacy criterion in two large, placebo-controlled trials, and its clinical utility is uncertain. Other potential treatments with varying mechanisms of action are currently under investigation. To date, no agent has been shown to significantly restore lost vision in patients with AMD. Future treatment strategies are likely to include a combination of treatments to better manage AMD-associated choroidal neovascularisation and preserve patients' visual acuity.

Donati G. · Clinique d'Ophtalmologie, Département de Neurosciences Cliniques, HCUG, 22 Rue A. Jentzer, 1211 Genève 14. · J Fr Ophtalmol. · Pubmed #12399734 links to  free full text

Abstract: Age-related macular degeneration (AMD) is currently the leading cause of severe visual acuity loss in people over the age of 50 in the Western world. Most of the visual loss is due to choroidal neovascularization (CNV). Laser photocoagulation is the only proven treatment for selected cases of AMD; however, it can only be used with less than 20% of patients at the time of diagnosis. Among experimental therapies currently being tested, photodynamic therapy has recently proven its efficacy in randomized multicenter studies for predominantly classic subfoveal pure occult type CNVs.

Donati G. · Clinique d'Ophtalmologie, Département de Neurosciences Cliniques, HCUG, 22 Rue A. Jentzer, CH-1211 Genève 14. · Klin Monatsbl Augenheilkd. · Pubmed #11417324 No free full text.

Abstract: INTRODUCTION: Age related macular degeneration (AMD) is actually the leading cause of severe visual acuity loss in people over 65 in the Western World. Most of the visual loss is due to choroidal neovascularization (CNV). METHODS: Review of the literature. RESULTS: For more then 10 years laser photocoagulation was the only proven treatment for selected cases of AMD according to the evidence based medicine criteria. In 1999 photodynamic therapy was proven to be efficient for the treatment of predominantly classic subfoveal CNV. CONCLUSION: Laser photocoagulation and photodynamic therapy constitute therefore the only evidence based medicine treatment available for CNV in AMD.

Donati G, Kapetanios AD, Pournaras CJ. · Department of Clinical Neurosciences, University Hospitals of Geneva, Geneva, Switzerland. · Semin Ophthalmol. · Pubmed #10790570 No free full text.

Abstract: Age-related macular degeneration (AMD) is a common cause of legal blindness in the developed countries in people older than 50 years of age. AMD complicated by choroidal neovascular membranes (CNV) accounts for 12% of AMD, but for 88% of legal blindness cases. Because of the progressive aging of the population, it is expected that AMD will be one of the greater public health problems in ophthalmology in the first half of the next century. Laser photocoagulation remains the only proven treatment for CNV in AMD, but unfortunately, is applicable only to a minority of patients presenting with CNV in AMD. Photodynamic therapy (PDT) is a new experiment treatment for CNV that combines the application of low-intensity light with a photosensitizing agent in the presence of oxygen to produce tissue effects. It uses the noninvasive potential of the laser light to cause a nonthermal localized chemotoxic reaction and obtain highly selective occlusion of the neovascular channels, with sparing of the overlying photoreceptors. Animal studies showed that PDT accounts for the effective closure of experimentally induced CNV. Phase I-II clinical studies showed that PDT using BPD can safely stabilize leakage from CNV in a majority of patients for up to 3 months. Phase III clinical studies to assess the long term prognosis of PDT-treatment of CNV in AMD are ongoing.

Donati G. · Clinique d'Ophtalmologie, Hôpitaux Universitaires Genevois, Genève, Suisse. · J Fr Ophtalmol. · Pubmed #16988631 links to  free full text

Abstract: INTRODUCTION: Photodynamic treatment (PDT) with verteporfin is used to treat choroidal subfoveal neovascularization in age-related macular degeneration (AMD). However, the impact of recurrence after PDT on functional results has not been assessed, although it was previously shown to be higher than 50% after thermal laser treatment for juxtafoveal lesions, and visual prognosis was dramatically worsened by recurrence of choroidal neovascularization. METHOD: Sixty-nine consecutive patients treated with PDT for CNV in AMD were followed every 3 months for up to 3 years. RESULTS: The observed recurrence rate was 17.4%. Recurrence was not associated with a decrease in visual acuity The average number of treatments was 3.0, increasing to 4.9 in case of recurrence. CONCLUSION: The recurrence rate is significantly lower after PDT than after thermal laser. It does not have a negative impact on functional outcome.

Blumenkranz MS, Bressler NM, Bressler SB, Donati G, Fish GE, Haynes LA, Lewis H, Miller JW, Monés JM, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Schachat AP, Schmidt-Erfurth U, Sickenburg M, Singerman LJ, Slakter JS, Strong A, Vannier S, Anonymous00194. · No affiliation provided · Arch Ophthalmol. · Pubmed #12365909 No free full text.

Abstract: OBJECTIVE: To report vision and safety outcomes from an extension of a 2-year investigation evaluating verteporfin photodynamic therapy in patients with age-related macular degeneration with subfoveal choroidal neovascularization (CNV). DESIGN AND SETTING: Open-label extension of selected patients from 2 multicenter, double-masked, placebo-controlled, randomized clinical trials, the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Investigation, at 22 ophthalmology practices in Europe and North America. PARTICIPANTS: Patients enrolled in the TAP Investigation and followed up for at least 24 months in whom verteporfin therapy to CNV might reduce the risk of further vision loss. METHODS: Before receiving verteporfin therapy in the extension, eligible patients signed a written informed consent form accompanied by an oral consent process approved by local institutional review boards. Methods were similar to those described for 1- and 2-year results, with follow-up examinations beyond 2 years continuing at 3-month intervals with a few exceptions, including that extension patients with fluorescein leakage from CNV were to receive open-label verteporfin therapy irrespective of their original treatment assignment. RESULTS: Of 402 patients in the verteporfin group, 351 (87.3%) completed the month 24 examination; 320 (91.2%) of these enrolled in the extension study. The enrolled participants included 124 (78.0%) of the 159 verteporfin-treated patients with lesions composed of predominantly classic CNV at baseline, of whom 105 (84.7%) completed the month 36 examination. Verteporfin-treated patients with this lesion composition at baseline who participated in the extension study, with or without a month 36 examination, appeared more likely to have a younger age, better level of visual acuity, absence of fluorescein leakage from classic CNV, or no progression of classic CNV beyond the baseline boundaries of the lesion at the month 24 examination compared with those who did not enroll in the extension. For the 105 patients with a predominantly classic baseline lesion composition who completed the month 36 examination, an average of 1.3 treatments were given from the month 24 examination up to, but not including, the month 36 examination. A letter score loss in the study eye of at least 15 from baseline for these patients occurred in 39 (37.5%) at the month 24 examination compared with 44 (41.9%) of these patients at the month 36 examination. Visual acuity changed little from the month 24 examination (mean, -1.9 lines) to the month 36 examination (mean, -2.0 lines) for these eyes. Verteporfin-treated patients had little change in the mean visual acuity lost and few or no additional instances of infusion-related back pain or photosensitivity reactions from month 24 to month 36. Two patients originally assigned to placebo had acute severe vision decrease within 7 days after verteporfin treatment during the extension. One patient originally assigned to verteporfin had acute severe vision decrease after verteporfin treatment of the fellow eye during the extension. CONCLUSIONS: Vision outcomes for verteporfin-treated patients with predominantly classic lesions at baseline remained relatively stable from month 24 to month 36, although only approximately one third of the verteporfin-treated patients originally enrolled with this lesion composition had a month 36 examination. From these results, the TAP Study Group identified no safety concerns to preclude repeating photodynamic therapy with verteporfin. Additional treatment was judged likely to reduce the risk of further vision loss. Caution appears warranted in the absence of comparison with an untreated group during the extension and since not all patients in the TAP Investigation participated in the TAP Extension.

Sickenberg M, Schmidt-Erfurth U, Miller JW, Pournaras CJ, Zografos L, Piguet B, Donati G, Laqua H, Barbazetto I, Gragoudas ES, Lane AM, Birngruber R, van den Bergh H, Strong HA, Manjuris U, Gray T, Fsadni M, Bressler NM. · Hopital Ophtalmique Jules Gonin, Lausanne, Switzerland. · Arch Ophthalmol. · Pubmed #10721954 No free full text.

Abstract: OBJECTIVE: To evaluate short-term safety and the effects on visual acuity and fluorescein angiography of single or multiple sessions of photodynamic therapy with verteporfin for choroidal neovascularization (CNV) not related to age-related macular degeneration (AMD), including pathologic myopia, the ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes. DESIGN: A nonrandomized, multicenter, open-label, dose-escalation phase 1 and 2 clinical trial. SETTING: Four ophthalmic centers in Europe and North America providing retinal care. PARTICIPANTS: Thirteen patients with subfoveal CNV due to pathologic myopia, the ocular histoplasmosis syndrome, angioid streaks, or idiopathic causes. METHODS: Standardized protocol refraction, visual acuity testing, ophthalmic examinations, color photographs, and fluorescein angiograms were used to evaluate the results of photodynamic therapy treatments with verteporfin. Follow-up ranged from 12 weeks for patients who were treated once to 43 weeks for patients who were treated up to 4 times. RESULTS: Verteporfin therapy was well tolerated in patients with CNV not related to AMD. No deterioration in visual acuity was observed; most patients gained at least 1 line of vision. Reduction in the size of leakage area from classic CNV was noted in all patients as early as 1 week after verteporfin therapy, with complete absence of leakage from classic CNV in almost half of the patients. Improvement in visual acuity after verteporfin therapy was greatest (+6, +8, and +9 lines) in 3 patients with relatively poor initial visual acuity (between 20/200 and 20/800). Up to 4 treatments were found to have short-term safety even with retreatment intervals as short as 4 weeks. CONCLUSIONS: Treatment of CNV not related to AMD with verteporfin therapy achieves short-term cessation of fluorescein leakage from CNV in a small number of patients without loss of vision. Further randomized clinical trials including a larger number of patients are under way to confirm whether verteporfin therapy is beneficial for subfoveal CNV not related to AMD.

Donati G, Kapetanios AD, Pournaras CJ. · Clinique Universitaire d'Ophtalmologie de Genève, Département des Neurosciences cliniques, Hôpitaux Universitaires de Genève, 1211 Genève 14, Suisse. · J Fr Ophtalmol. · Pubmed #10660648 links to  free full text

Abstract: PURPOSE: Age related macular degeneration (AMD) is the most common cause of legal blindness in the Western world in people over 50 years of age. The most severe visual loss occurs in patients with AMD complicated by choroidal neovascular membranes (CNV). Indocyanine green angiography (ICG) account for visualization in up to 60% of the cases that are classified as occult on fluorescein angiography (up to 70% of the cases). ICG-guided laser photocoagulation of CNV is currently a mater of debate. We conducted a pilot study to determine wether it could be beneficial for patients presenting with occult CNV on fluorescein angiography. MATERIAL AND METHODS: Twenty consecutive patients (20 eyes) with occult CNV in AMD were included. All showed occult CNV on fluorescein angiography and a well defined juxta- or extrafoveal hot spot or plaque hyperfluorescence on ICG. Fibrovascular retinal pigment epithelial detachments were excluded. The patients had serial controls, including fluorescein angiography and ICG, at 15 days, 1, 2, 3, 6, 9 and 12 months after photocoagulation. RESULTS: At the end of follow-up visual acuity (VA) was stable (within +/- 3 lines) compared to the initial one in 80% (16) of the cases. A complete resolution of exudative signs was observed in 75% (15) of the cases. CONCLUSIONS: ICG-guided laser photocoagulation of occult CNV in AMD account for better visual acuity than natural course of the disease at 12 months follow-up. However, a prospective randomized clinical trial is warranted to evaluate definitively this treatment approach.

Schmidt-Erfurth U, Miller JW, Sickenberg M, Laqua H, Barbazetto I, Gragoudas ES, Zografos L, Piguet B, Pournaras CJ, Donati G, Lane AM, Birngruber R, van den Berg H, Strong HA, Manjuris U, Gray T, Fsadni M, Bressler NM. · Retina Department, University Eye Hospital, Lübeck, Germany. · Arch Ophthalmol. · Pubmed #10496389 No free full text.

Abstract: OBJECTIVES: To evaluate safety and short-term visual acuity and fluorescein angiographic effects of photodynamic therapy (PDT) after retreatments with verteporfin for choroidal neovascularization (CNV) in age-related macular degeneration (AMD) that demonstrated fluorescein leakage after at least 1 course of PDT. DESIGN: Nonrandomized, multicenter, open-label phase 1 and 2 clinical trial using 2 different retreatment dosage regimens. SETTING: Four ophthalmic centers in Europe and North America providing retinal care. METHODS: Standardized protocol refraction, visual acuity testing, ophthalmic examinations, color photographs, and fluorescein angiograms were used to evaluate the results of multiple PDT treatments. Two regimens (regimens 2 and 4) for treatment and retreatment were chosen from 5 used in a single-treatment study. Both regimens used a verteporfin dose of 6 mg/m2 infused for 10 minutes. However, regimen 2 used a light dose of 100 J/cm2 applied 20 minutes after the start of the verteporfin infusion, whereas regimen 4 used a light dose of 50, 75, or 100 J/cm2 applied 15 minutes after infusion commenced. Posttreatment evaluations were planned in 31 participants up to 3 months after up to 2 retreatments given at 2- or 4-week intervals after initial PDT treatment. Similar posttreatment evaluations were planned after retreatments in 5 additional participants who were reenrolled some time more than 12 weeks after an initial PDT treatment. RESULTS: The average visual acuity change for the 31 participants who had retreatment within 2 to 4 weeks after the initial treatment and a follow-up examination 16 to 20 weeks after the initial treatment was 0.2 lines (range, -4 to 4 lines) in regimen 2 and -1.0 line (range, -5 to 3 lines) in regimen 4. Similar outcomes were noted in the 5 reenrolled participants. Cessation of fluorescein leakage from classic CNV for at least 1 to 4 weeks could be achieved without loss of visual acuity after at least 2 treatments in 2 (6.5%) of 31 patients. Similar to single-treatment effects, the disappearance of leakage was documented regularly at 1 week after each retreatment. Fluorescein leakage reappeared by 4 to 12 weeks after a retreatment in almost all cases. However, compared with baseline, leakage activity appeared to be reduced after multiple PDT courses. For the 31 patients who had follow-up for 3 months after the last retreatment and had received retreatment 2 to 4 weeks after the initial treatment, progression of CNV beyond the area identified before the retreatment was noted in 10 (48%) of the 21 eyes with classic CNV in regimen 2 and 9 (90%) of 10 eyes in regimen 4. The rate and severity of ocular or systemic adverse events were not increased by multiple applications. CONCLUSIONS: Multiple applications of PDT with verteporfin achieve repetitive, short-term cessation of fluorescein leakage from CNV secondary to AMD, without loss of visual acuity. This strategy can be used in randomized clinical trials investigating the efficacy of verteporfin in PDT for recurrent fluorescein dye leakage from persistent or recurrent CNV, following an initial or subsequent PDT treatment, with maintenance of visual acuity. Retreatments may achieve progressive cessation of leakage and prevent further growth of CNV and subsequent visual loss.

Miller JW, Schmidt-Erfurth U, Sickenberg M, Pournaras CJ, Laqua H, Barbazetto I, Zografos L, Piguet B, Donati G, Lane AM, Birngruber R, van den Berg H, Strong A, Manjuris U, Gray T, Fsadni M, Bressler NM, Gragoudas ES. · Retina Service, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, USA. · Arch Ophthalmol. · Pubmed #10496388 No free full text.

Abstract: OBJECTIVE: To evaluate the safety and short-term visual and fluorescein angiographic effects of a single photodynamic therapy treatment with verteporfin with the use of different dosage regimens in patients with choroidal neovascularization (CNV) from age-related macular degeneration. DESIGN: Nonrandomized, multicenter, open-label, clinical trial using 5 dosage regimens. SETTING: Four ophthalmic centers in North America and Europe providing retinal care. PARTICIPANTS: Patients with subfoveal CNV caused by age-related macular degeneration. METHODS: Standardized protocol refraction, visual acuity testing, ophthalmic examination, color photographs, and fluorescein angiograms were used to evaluate the effects of a single treatment of photodynamic therapy with verteporfin. Follow-up was planned through 3 months in 97 patients and for less than 3 months in 31 other patients. RESULTS: The mean visual acuity change (and range of change) from baseline at the follow-up examination at week 12 after a single treatment with regimens 1 through 5 was -0.2 (-3 to +2), -0.9 (-9 to +5), -1.6 (-9 to +2), +0.4 (-8 to +7), and +0.1 (-8 to +9) lines, respectively. Only the highest light dose (150 J/cm2) in regimens 2 and 3, which produced angiographic nonperfusion of neurosensory retinal vessels, caused marked vision loss. Some cessation of fluorescein leakage from CNV was achieved without loss of vision when the light dose used was less than 150 J/cm2. Systemic adverse events were rare. Cessation of fluorescein leakage from CNV was noted in all regimens by 1 week after photodynamic therapy. Fluorescein leakage from at least a portion of the CNV reappeared by 4 to 12 weeks after treatment in almost all cases. Progression of classic CNV beyond the area of CNV identified before treatment was noted in 42 (51%) of the 83 eyes with classic CNV followed up for 3 months after a single treatment. Eyes in which the area of any CNV leakage at 12 weeks was less than at baseline had a significantly better visual acuity outcome (+0.8 line) than eyes in which CNV leakage progressed (-0.8 line). CONCLUSIONS: Photodynamic therapy with verteporfin achieved short-term cessation of fluorescein leakage from CNV without loss of vision or growth of classic CNV in some patients with age-related macular degeneration. Except for nonperfusion of neurosensory retinal vessels at a light dose of 150 J/cm2, no other adverse events were of concern. Randomized clinical trials to investigate whether this new modality can preserve vision in patients with CNV secondary to age-related macular degeneration are justified.

Donati G. · Service d'Ophtalmologie, Hôpitaux Universitaires de Genève. · J Fr Ophtalmol. · Pubmed #17978682 links to  free full text

Abstract: OBJECTIVES: Age-related macular degeneration is the leading cause of legal blindness in older people. Choroidal neovascularization (CNV) is treatable with photodynamic therapy with verteporfin (PDT) but is expensive. The aim of this study was to assess the cost-effectiveness of PDT in routine clinical practice in Switzerland. MATERIALS AND METHODS: A Markov model was used to analyze the costs of PDT in routine clinical practice. It described patients moving between good or impaired vision (visual acuity [VA]>0.1) and highly impaired vision (VA<0.1). Costs for PDT were based on the results of the Donati open-labeled prospective clinical study. Costs for medical and social management of AMD patients were defined according to Grainer's study. RESULTS: The cost of PDT varied from 8,800 to 10,969 euros/patient/year. Ninety percent of the patients retained a VA > or =0.1. Health costs saved by keeping patients from moving to the highly impaired vision group was 4,248 euros/patient/year. Incremental costs per vision-year saved varied from 8,239 to 10,271 euros. Cost per quality-adjusted life year (QALY) gained at 5 years was 65,150 euros. DISCUSSION: PDT was found to be moderately cost-effective in Switzerland. The longer the follow-up, the more cost-effective Visudyne was. Cost-effectiveness is a country-dependent assessment and analyses should be done for each health care system. CONCLUSION: PDT was found to be cost-effective in Switzerland (category C of Laupaci's classification).

Donati G, Christiaen MP. · Clinique d'Ophtalmologie, Service du professeur A. B. Safran, Hôpitaux Universitaires Genevois, Geneva, Switzerland. · Klin Monatsbl Augenheilkd. · Pubmed #16705501 No free full text.

Abstract: PURPOSE: The aim of this study was to establish the prevalence of visual impairment in the elderly population in geriatric homes in an urban area. PATIENTS AND METHODS: A sample of 96 patients from 8 geriatric homes ["Etablissements Médico-Sociaux" (EMS)] in the Geneva area were examined. The NEI-VFQ-25 modified questionnaire was used. Visual acuity examination (far and near), contrast visual acuity measurement and enlargement need were administered by low vision trainers. RESULTS: Of the 96 patients 42 % were partially sighted and 3 % blind. Self assessment of visual performance disclosed that 31 % of the patients complained about bad vision but only 12 % were worried about their vision. Cataract, age-related macular degeneration, glaucoma and diabetes were the most frequent diagnosis associated to visual disability. DISCUSSION: The prevalence of the visual handicap in the elderly geriatric population is very high, but most of the patients are neither aware, nor worried about their handicap. This maybe related to associated general health disabling diseases.

Blinder KJ, Bradley S, Bressler NM, Bressler SB, Donati G, Hao Y, Ma C, Menchini U, Miller J, Potter MJ, Pournaras C, Reaves A, Rosenfeld PJ, Strong HA, Stur M, Su XY, Virgili G, Anonymous00153, Anonymous00154. · · Am J Ophthalmol. · Pubmed #12967792 No free full text.

Abstract: PURPOSE: To determine whether differences in baseline lesion size and visual acuity might explain differing results found in three different lesion compositions (predominantly classic, minimally classic, and occult with no classic) among three placebo-controlled, randomized clinical trials evaluating photodynamic therapy with verteporfin (Visudyne, Novartis AG), also termed verteporfin therapy, in patients with subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration (AMD). METHODS: Exploratory analyses were conducted in patients with predominantly classic or minimally classic lesions at enrollment in the Treatment of AMD with Photodynamic Therapy (TAP) Investigation and in AMD patients with occult with no classic CNV in the Verteporfin In Photodynamic Therapy (VIP) Trial. Baseline characteristics of patients among these three lesion compositions were compared. In addition, multiple linear regression modeling was used to explore the effect of baseline lesion size, visual acuity, and lesion composition on mean change in visual acuity from baseline to 24 months. RESULTS: At baseline, the mean size of predominantly classic lesions (3.4 disk areas) was smaller than that of minimally classic (4.7 disk areas) and occult with no classic lesions (4.3 disk areas). In the multiple linear regression model of individual lesion compositions, there was a significant treatment-by-lesion-size interaction for minimally classic and occult with no classic lesions, but not for predominantly classic lesions. Interaction between treatment and baseline visual acuity was not significant for any lesion composition. Small verteporfin-treated lesions lost less vision than large verteporfin-treated lesions in each lesion composition. In the multiple linear regression model that included all lesion compositions, lesion size was a more significant predictive factor for the magnitude of treatment benefit than either lesion composition or visual acuity. Smaller (4.0 disk areas or less) minimally classic and occult with no classic lesions had similar visual acuity outcomes to those observed in predominantly classic lesions. CONCLUSIONS: Based on exploratory analyses, lesion size in the TAP Investigation and VIP Trial was an important predictor of the magnitude of treatment benefit with verteporfin therapy in occult with no classic and minimally classic lesion compositions. In patients with AMD, treating smaller rather than larger neovascular lesions, regardless of lesion composition, likely will result in a better level of visual acuity.

Pournaras CJ, Kapetanios AD, Donati G. · University Eye Department, University Hospitals of Geneva, Switzerland. · Doc Ophthalmol. · Pubmed #10896362 No free full text.

Abstract: PURPOSE: Traction macular edema may develop through contraction of macular epiretinal membranes (ERM), or due to persistent vitreomacular traction during the evolution of vitreomacular traction syndrome (VMS). The purpose of this retrospective study was to determine the effect of vitreous surgery and the release of the vitreomacular traction or the removal of epiretinal membranes, on the evolution of traction induced macular edema. MATERIAL AND METHODS: Fourteen eyes from 14 patients presenting with idiopathic or secondary epiretinal membranes, and 11 eyes from 10 patients presenting with vitreomacular traction syndrome, underwent vitrectomy for reduced vision and cystoid macular edema, identified by slit-lamp examination and fluorescein angiography. No coexistent ocular conditions that might have caused macular traction were present. History, preoperative eye examination, operative findings, postoperative course and final examination as well as pre- and postoperative fluorescein angiography were reviewed. RESULTS: In the ERM group, cystoid macular edema disappeared in all cases during the postoperative period and the mean visual acuity (VA) at the end of the follow-up (0.48 +/- 0.23) significantly increased compared to the preoperative one (0.29 +/- 0.2) (p=0.004). In the group of patients suffering from VMS, the posterior vitreous traction on the macula was released and macular edema disappeared in all cases but one. The mean v.a. at the end of the follow-up (0.42 +/- 0.24) significantly increased compared to the preoperative one (0.18 +/- 0.1) (p=0.01). Complications included intraoperative small petechias and postoperative progressive nuclear sclerosis, retinal detachment and retinal pigment epitheliopathy. CONCLUSIONS: Cystoid macular edema may develop secondary to vitreomacular traction syndrome or epiretinal membrane contraction. Vitrectomy is effective in releasing macular traction which, in turn, may induce a decrease of the macular edema with improvement of visual acuity.

Donati G, Kapetanios AD, Pournaras CJ. · Ophthalmology, Department of Clinical Neurosciences, University of Geneva Hospitals, CH-1211 Geneva 14, Switzerland. · Graefes Arch Clin Exp Ophthalmol. · Pubmed #10541896 No free full text.

Abstract: BACKGROUND: The most common cause of legal blindness in the Western world in people over 50 years of age is age-related macular degeneration (AMD) complicated by choroidal neovascular membranes (CNV). We conducted a prospective pilot study to evaluate the functional and anatomical results of indocyanine green (ICG)-guided laser photocoagulation of juxta- and extrafoveal occult CNV. METHODS: Seventeen consecutive patients (17 eyes) with occult CNV in AMD were included. All showed occult CNV appearing as late-phase fluorescein leakage of undetermined source on fluorescein angiography and as a well-defined hot spot or plaque hyperfluorescence on ICG angiography. Fibrovascular retinal pigment epithelial detachments (PED) and serohemorrhagic PED were excluded. Laser photocoagulation was performed using an argon green laser. The patients had serial follow-up examinations, including fluorescein and ICG angiography, at 15 days and 1, 2, 3, 6, 9 and 12 months after photocoagulation. RESULTS: At the end of the follow-up, the visual acuity (VA) was stable (within +/-3 lines of the initial VA) in 76% (13) of the eyes. A moderate decrease in VA was observed in 24% (4). A complete resolution of exudative signs was observed in 65% (11). CONCLUSION: ICG-guided laser photocoagulation of occult CNV, presenting at baseline examination as late-phase fluorescein leakage of undetermined source and as a well-defined hyperfluorescent lesion on ICG angiography, may constitute a subgroup of occult CNV that benefits from ICG-guided laser photocoagulation. A multicentric randomized controlled clinical study is, however, mandatory to confirm this result.

Donati G, Kapetanios AD, Pournaras CJ. · Département des Neurosciences Cliniques, Hôpitaux Universitaires de Genève. · Klin Monatsbl Augenheilkd. · Pubmed #10420365 No free full text.

Abstract: MATERIAL AND METHODS: Preoperative findings, intraoperative and postoperative complications as final results of 70 consecutive cases of idiopathic or secondary ERM operated by the same retina surgeon were analyzed. RESULTS: In all cases the ERMs were successfully removed from the fovea. The mean v.a. increased from 0.34 +/- 0.2. to 0.54 +/- 0.31, (p < 0.05) postoperatively. Idiopathic and secondary ERMs both showed significant improvement after surgery. Complications included intraoperative hemorrhage and retinal tears. Postoperative progressive nuclear sclerosis, retinal tears causing detachments, macular edema and retinal pigmentary epitheliopathy. CONCLUSIONS: Performing surgery for ERMs is worthwhile on eyes with major decreased v.a. and on eyes with metamorphopsia but only moderately reduced vision. Postoperative complications are frequent but can usually be managed successfully. Of them only retinal detachment is of some worse prognosis on the final functional outcome.

Donati G, Soubrane D, Quaranta M, Coscas G, Soubrane G. · Eye Clinic, Department of Clinical Neurosciences, University Hospitals of Geneva. · Br J Ophthalmol. · Pubmed #10340969 links to  free full text

Abstract: BACKGROUND/AIMS: Teletherapy has been proposed as a possible treatment for choroidal neovascular membranes (CNV), secondary to age related macular degeneration (AMD) not amenable to laser photocoagulation. The aim of this prospective study has been to investigate the effect of teletherapy on isolated occult choroidal neovascular membranes of subfoveal location. METHODS: 28 AMD patients presenting with retrofoveal isolated occult CNV demonstrated by fluorescein angiography were treated by external beam radiation. A complete ophthalmological examination, fluorescein angiography, and indocyanine green angiography (ICG) were performed within 15 days before treatment and repeated at follow up. A total dose of 16 Gy was applied in four sessions of 4 Gy using a 4 MeV photon beam. Follow up ranged from 6 to 9 months (mean follow up 6.4 months). RESULTS: Visual acuity was found to be stable in 68% of the cases. The decrease in visual acuity was of 3-6 lines in 18% and of more than 6 lines in 10% of the eyes at last examination. On fluorescein angiography the size of the lesion area was found to be stable in 67%, decreased in 13%, and increased in 20% of the cases. On ICG angiography the size of the CNV was stable in 93% and increased in 7% of the cases. All the eyes experiencing a visual acuity decrease showed either no change or an increase in size of the membrane on fluorescein angiography and/or on ICG. CONCLUSION: According to this study with strict inclusion criteria, external beam radiotherapy seems to have a beneficial effect on the evolution of isolated occult subfoveal CNV.